Peningkatan Kadar Bilirubin Total Serum dan Kaitannya dengan Derajat Klinis Pasien Covid-19

Elevation of Total Bilirubin Serum and Its Correlation with Clinical State of Covid-19 Patient

Authors

  • Tiene Rostini Departemen Patologi Klinik, Fakultas Kedokteran Universitas Padjadjaran/ Rumah Sakit Umum Pusat Dokter Hasan Sadikin Bandung, Indonesia
  • Laila Kurnia Pramono Program Studi Patologi Klinik Fakultas Kedokteran Universitas Padjadjaran/ Rumah Sakit Umum Pusat Dokter Hasan Sadikin Bandung, Indonesia
  • Anna Tjandrawati Departemen Patologi Klinik, Fakultas Kedokteran Universitas Padjadjaran/ Rumah Sakit Umum Pusat Dokter Hasan Sadikin Bandung, Indonesia
  • Raja Iqbal Mulya Harahap Departemen Patologi Klinik, Fakultas Kedokteran Universitas Padjadjaran/ Rumah Sakit Umum Pusat Dokter Hasan Sadikin Bandungathology, Faculty of Medicine, Universitas Padjadjaran, Indonesia

DOI:

https://doi.org/10.36408/mhjcm.v9i2.697

Keywords:

Bilirubin, COVID-19, Derajat Klinis

Abstract

Latar belakang : Reseptor utama SARS-CoV-2, yaitu Angiotensin Converting Enzyme-2 (ACE-2) diekspresikan secara luas pada tubuh manusia. Derajat klinis infeksi Coronavirus Disease 2019 (COVID-19) bervariasi, dan diklasifikasikan menjadi asimtomatik, sakit ringan, sakit sedang, sakit berat, dan kritis. Peningkatan kadar bilirubin total serum sering dihubungkan dengan derajat klinis penyakit serta mortalitas COVID-19. Penelitian ini bertujuan untuk mengetahui peningkatan kadar bilirubin total serum dan hubungannya dengan derajat klinis infeksi COVID-19

Metode : Desain penelitian adalah cross sectional dengan pengambilan data secara simple random sampling. Data yang dikumpulkan sebanyak 73 sampel yang berasal dari RSUP Dr. Hasan Sadikin dalam periode Mei–Desember 2020. Data bilirubin total dan derajat klinis infeksi COVID-19 dianalisis menggunakan Uji Mann-Whitney dan Uji Spearman untuk mendapatkan hubungan antara kedua variabel.

Hasil : Hasil penelitian ini menunjukkan laki-laki lebih banyak dari perempuan, dengan dominasi subjek berusia 46–65 tahun, yaitu sebanyak 47,9% dari keseluruhan sampel. Median kadar bilirubin total serum pada infeksi COVID-19 derajat klinis berat-kritis lebih tinggi dibandingkan derajat klinis sedang (0,8 mg/dl vs 0,4 mg/dl), dengan koefisien r sebesar 0,463 (p<0,05).

Simpulan : Peningkatan kadar bilirubin total serum berhubungan dengan derajat klinis infeksi COVID-19 di RSUP Dr. Hasan Sadikin Bandung. Penelitian lebih lanjut dapat dilakukan secara kohort prospektif yang mengukur kadar bilirubin total serum secara serial dan menilai outcome subjek penelitian.

Downloads

Download data is not yet available.

References

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020.

World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. Geneva: World Health Organization; 2020.

Zhou P, Yang -L, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.

Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta- analysis. The lancet Gastroenterology & hepatology, 2020; 5(7): 667–678.

Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United European gastroenterology journal. 2020: 509–519.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020.

Pedoman Pencegahan dan Pengendalian COVID19. Kementerian Kesehatan Republik Indonesia, 2020.

Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M, et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver International. 2021: 41(1): 20–3

Morgan K, Samuel K, Vandeputte M, Hayes PC, Plevris JN. SARS-CoV-2 infection and the liver. Pathogens. 2020: 430.

Gupta A, Madhavan M V, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID- 19. Nature medicine, 2020, 26(7), 1017–1032.

Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. medRxiv Preprint 19 February 2020.

Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. American journal of respiratory and critical care medicine, 2020, 201(11), 1380–1388.

Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A tool to early predict severe corona virus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China. Clin Infect Dis. (2020) 71:833–40.

Liu Z, Li J, Long W, Zeng W, Gao R, Zeng G, et al. Bilirubin levels as potential indicators of disease severity in coronavirus disease patients: A retrospective cohort study. Frontiers in medicine. 2020: 7.

Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia, 2020, 34(8), 2173.

Liu Z, Li J, Long W, et al. Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study. Front Med (Lausanne). 2020;7:598870. Published 2020 Nov 9. doi:10.3389/ fmed.2020.598870

Essa R A, Ah me d SK , Ba p i r D H , Ab u b a k r C P . Hyperbilirubinemia with mild COVID-19 patient: A case r e p o r t . I n t J S u r g C a s e R e p . 2 0 2 1 ; 8 2 : 1 0 5 9 5 8 . doi:10.1016/j.ijscr.2021.105958

Paliogiannis P, Zinellu A. Bilirubin levels in patients with mild and severe Covid-19: A pooled analysis. Liver Int. 2020;40(7):1787–1788. doi:10.1111/liv.14477

Additional Files

Published

2022-07-30

How to Cite

1.
Rostini T, Kurnia Pramono L, Tjandrawati A, Harahap RIM. Peningkatan Kadar Bilirubin Total Serum dan Kaitannya dengan Derajat Klinis Pasien Covid-19: Elevation of Total Bilirubin Serum and Its Correlation with Clinical State of Covid-19 Patient. Medica Hospitalia J. Clin. Med. [Internet]. 2022 Jul. 30 [cited 2024 Dec. 22];9(2):117-21. Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/697

Issue

Vol. 9 No. 2 (2022): Med Hosp; Juli 2022

Section

Original Article

Citation Check

License

Copyright (c) 2022 Tiene Rostini, Laila Kurnia Pramono, Anna Tjandrawati, Raja Iqbal Mulya Harahap

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.